Sienna Biopharmaceuticals (Sienna Biopharmaceuticals) Interest Expense : $0.00 Mil (TTM As of Sep. 2019)

View and export this data going back to 2017. Start your Free Trial

What is Sienna Biopharmaceuticals Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Sienna Biopharmaceuticals's interest expense for the three months ended in Sep. 2019 was $ 0.00 Mil. Its interest expense for the trailing twelve months (TTM) ended in Sep. 2019 was $0.00 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Sienna Biopharmaceuticals's Operating Income for the three months ended in Sep. 2019 was $ -8.84 Mil. Sienna Biopharmaceuticals's Interest Expense for the three months ended in Sep. 2019 was $ 0.00 Mil. Sienna Biopharmaceuticals has no long-term debt ⁽¹⁾. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

(1) Note: An indication of "no long-term debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

Sienna Biopharmaceuticals Interest Expense Historical Data

The historical data trend for Sienna Biopharmaceuticals's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sienna Biopharmaceuticals Interest Expense Chart

Sienna Biopharmaceuticals Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Interest Expense

-0.57

Sienna Biopharmaceuticals Quarterly Data
	Dec15	Mar16	Jun16	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19
Interest Expense	Get a 7-Day Free Trial											-	-	-	-	-

Sienna Biopharmaceuticals Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Sep. 2019 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

Sienna Biopharmaceuticals (OTCPK:SNNAQ) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Sienna Biopharmaceuticals's Interest Expense for the three months ended in Sep. 2019 was $0.00 Mil. Its Operating Income for the three months ended in Sep. 2019 was $-8.84 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Sep. 2019 was $0.00 Mil.

Sienna Biopharmaceuticals's Interest Coverage for the quarter that ended in Sep. 2019 is calculated as

Sienna Biopharmaceuticals had no long-term debt ⁽¹⁾.

The higher the ratio, the stronger the company's financial strength is.

Sienna Biopharmaceuticals (Sienna Biopharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sienna Biopharmaceuticals Inc (OTCPK:SNNAQ) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

N/A

Address

30699 Russell Ranch Road, Suite 140, Westlake Village, CA, USA, 91362

Website

http://www.SiennaBio.com

Sienna Biopharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on bringing innovations in biotechnology to the discovery, development, and commercialization of first-in-class, targeted, topical products in medical dermatology and aesthetics. The objective is to develop multi-asset pipeline of topical therapies that enhance the health, appearance, and quality of life of dermatology patients. The product portfolio includes SNA-120, SNA-125, and SNA-001.

Executives

Alexander Azoy	officer: Chief Financial Officer	30699 RUSSELL RANCH ROAD, SUITE 140, WESTLAKE VILLAGE CA 91362
Timothy K. Andrews	officer: General Counsel & Secretary	30699 RUSSELL RANCH ROAD, SUITE 140, WESTLAKE VILLAGE CA 91362
Iii Frederick Beddingfield	director, officer: President & CEO	C/O KYTHERA BIOPHARMACEUTICALS, INC. 27200 WEST AGOURA ROAD, SUITE 200 CALABASAS CA 91301
Paul F. Lizzul	officer: Chief Medical Officer	30699 RUSSELL RANCH ROAD, SUITE 140, WESTLAKE VILLAGE CA 91362
Diane Stroehmann	officer: See Remarks	30699 RUSSELL RANCH ROAD SUITE 140 WESTLAKE VILLAGE CA 91362
Dennis M Fenton	director
Todd Harris	director	30699 RUSSELL RANCH ROAD, SUITE 140, WESTLAKE VILLAGE CA 91362
Kristina Burow	director, 10 percent owner	8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631
Robert J More	director	680 S CACHE STREET, SUITE 100, BOX 10820, JACKSON WY 83001
James M. Hindman	director	2525 DUPONT DRIVE, IRVINE CA 92612
Keith R Leonard	director	ARYX THERAPEUTICS,INC., 6300 DUMBARTON CIRCLE, FREMONT CA 94555
Arch Venture Partners Viii, L.p.	10 percent owner	8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631
Arch Venture Fund Viii Overage, L.p.	10 percent owner	C/O ARCH VENTURE PARTNERS VIII, LLC, 8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631
Arch Venture Fund X Overage, L.p.	10 percent owner	8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631
Arch Venture Partners X Overage, L.p.	10 percent owner	8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631